Havana, Cuba, Jun 30.- Heberprot-P, developed by the Center for Genetic Engineering and Biotechnology (CIGB by its Spanish acronym), is patented in over 30 nations, including USA and the European Union, experts form this institution announced in this city. M.Sc. Ernesto López, CIGB business director, exclusively told ACN the list also includes Canada, Argentina, Australia, Hong Kong, Singapore, South Korea, South Africa, Russia, China, India, Indonesia, Ukraine, Mexico, Malaysia, Japan and Cuba, and the license was presented in Brazil, Thailand and Chile.
Lopez said that this Cuban biotechnology product, effective for the treatment of diabetic foot ulcers, has health registrations since 2008 in countries like Algeria, Argentina, Uruguay, the Dominican Republic, Venezuela, Ecuador, Mexico, Paraguay, Libya, Colombia, Guatemala, Georgia, Ukraine, Vietnam, the Philippines, Panama, Peru, El Salvador, Russia and Cuba.
To date 146 patients have been treated with the drug, including clinical trials and national and international programs; and more than 31 000 are Cubans, Mailyn Palmero, promoter of the product that is administered by intralesional infiltration to accelerate healing of deep and complex ulcers, both neuropathic and ischemic.
Experts say it also reduces the risk of lower extremity amputation and it has been extended to the Primary Health Care in Cuba.
Heberprot-P, registered in the Caribbean nation since 2006, and included in the basic drugs and approved for marketing, leads CIGB, which was founded by the historic leader of Cuban Revolution Fidel Castro on July 1986.
Meanwhile, PhD Rolando Paez, CIGB director of development, explained that scientists are now working in other generations, from three variants including (non-injectable) topical form.
The investigators´ strategy is having available any of these new products, which already have exclusive intellectual property internationally, before 2022, when the current Heberprot-P patent expires. (acn).